Discovery of Novel Coumarin-Schiff Base Hybrids as Potential Acetylcholinesterase Inhibitors: Design, Synthesis, Enzyme Inhibition, and Computational Studies. 2023

Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
Department of Chemistry, Faculty of Science, University Teknologi Malaysia, Johor Bahru 81310, Johor, Malaysia.

To discover anti-acetylcholinesterase agents for the treatment of Alzheimer's disease (AD), a series of novel Schiff base-coumarin hybrids was rationally designed, synthesized successfully, and structurally characterized using Fourier transform infrared (FTIR), Nuclear magnetic resonance (NMR), and High-Resolution Mass Spectrometry (HRMS) analyses. These hybrids were evaluated for their potential inhibitory effect on acetylcholinesterase (AChE). All of them exhibited excellent inhibitory activity against AChE. The IC50 values ranged from 87.84 to 515.59 μg/mL; hybrids 13c and 13d with IC50 values of 0.232 ± 0.011 and 0.190 ± 0.004 µM, respectively, showed the most potent activity as acetylcholinesterase inhibitors (AChEIs). The reference drug, Galantamine, yielded an IC50 of 1.142 ± 0.027 µM. Reactivity descriptors, including chemical potential (μ), chemical hardness (η), electrophilicity (ω), condensed Fukui function, and dual descriptors are calculated at wB97XD/6-311++ G (d,p) to identify reactivity changes of the designed compounds. An in-depth investigation of the natural charge pattern of the studied compounds led to a deep understanding of the important interaction centers between these compounds and the biological receptors of AChE. The molecular electrostatic surface potential (MESP) of the most active site in these derivatives was determined using high-quality information and visualization. Molecular docking analysis was performed to predict binding sites and binding energies. The structure-activity-property relationship studies indicated that the proposed compounds exhibit good oral bioavailability properties. To explore the stability and dynamic behavior of the ligand-receptor complexes, molecular dynamics simulations (MDS) were performed for 100 ns on the two best docked derivatives, 13c and 13d, with the AChE (4EY7) receptor. A popular method for determining the free binding energies (MM/GBSA) is performed using snapshots taken from the systems' trajectories at 100 ns. These results revealed that the complex system of compound 13d acquired a relatively more stable conformation and exhibited better descriptors than the complex system of compound 13c and the Galantamine drug, suggesting its potential as an effective inhibiting drug. The binding free energy analysis revealed that the 13d-4EY7 complex exhibited greater stability with AChE receptors compared to other complexes.

UI MeSH Term Description Entries

Related Publications

Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
January 2016, Anti-cancer agents in medicinal chemistry,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
March 2022, Molecules (Basel, Switzerland),
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
May 2021, Bioorganic chemistry,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
September 2014, Archiv der Pharmazie,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
January 2023, Journal of biomolecular structure & dynamics,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
April 2024, Future medicinal chemistry,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
November 2018, Journal of fluorescence,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
October 2016, Bioorganic & medicinal chemistry,
Aso Hameed Hasan, and Faruq Azeez Abdulrahman, and Ahmad J Obaidullah, and Hadil Faris Alotaibi, and Mohammed M Alanazi, and Mahmoud A Noamaan, and Sankaranarayanan Murugesan, and Syazwani Itri Amran, and Ajmal R Bhat, and Joazaizulfazli Jamalis
May 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!